Skip to main content

Posts

Showing posts with the label MiNK Therapeutics

Featured Post

Market Daily Report: Bursa Malaysia Ends Nearly Flat As Construction Stocks Attract Buying

 KUALA LUMPUR, Sept 8 (Bernama) -- Bursa Malaysia closed almost flat on Tuesday as buying interest rotated away from index heavyweights towards smaller-cap construction stocks, with sentiment affected by geopolitical uncertainty, said an analyst. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) eased 0.39 of a point to 1,714.40 from Monday’s close of 1,714.79. The benchmark index opened 1.65 points lower at 1,713.14 and moved between 1,710.44 and 1,714.50 throughout the trading session. The broader market was almost evenly balanced, with decliners leading gainers 548 to 546, while 598 counters were unchanged, 1,107 were untraded and 25 were suspended. Turnover expanded to 4.13 billion units valued at RM3.14 billion from 3.60 billion units valued at RM2.45 billion on Monday.

MiNK Therapeutics Soars 700% on Breakthrough Cancer Remission Case

MiNK Therapeutics ($INKT), a nano-cap clinical-stage biotech firm, shocked the market Friday with a  massive surge of over 700% , driven by a  landmark cancer remission case  published in  Nature's Oncogene . What Happened? MiNK announced a  complete and durable remission  in a patient with  metastatic, treatment-refractory testicular cancer . The patient had failed multiple prior therapies and received a  single infusion  of MiNK’s proprietary  agenT-797 iNKT cell therapy , combined with  Bristol Myers Squibb’s ($BMY) Opdivo (nivolumab) . ✅  Outcome:  Two years later,  no evidence of disease , with the treatment well-tolerated —  no cytokine release syndrome (CRS)  or  graft-versus-host disease (GVHD) . This case marks a critical validation point for agenT-797’s potential in treating  solid tumors  — a notoriously tough challenge in oncology. Other Clinical Highlights At the  2025 AACR I...